Cardiovascular health remains a critical global concern, with heart disease standing as the number one cause of death worldwide. In 2019, approximately 32% of all deaths were caused by heart-related conditions, with heart attacks and strokes accounting for 85% of these fatalities. Despite advances in medical science, many heart-related issues continue to be preventable through proper understanding and management of cardiovascular wellness.
For supplement manufacturers seeking clinically-validated ingredients to address this widespread health challenge, Omega-7 fatty acids offer a compelling solution. Notably, research demonstrates that Omega-7supplementation can significantly reduce C-Reactive Protein (CRP) by 44%,triglycerides by 15%, and Low-Density Lipoprotein (LDL) by 8% . Furthermore, studies show remarkable improvements in heart health markers, including a 30%reduction in serum triglycerides, 23% decrease in LDL, and 12% reduction in blood sugar, while simultaneously increasing beneficial HDL cholesterol by 7% .
Among natural sources of this valuable fatty acid, SeaBuckthorn oil stands out as the most potent botanical source, containing omega-7 concentrations ranging from 19% to 29%. However, Puredia’s CardiOmegia™has set a new industry standard with an exceptional 45% omega-7 content—the highest concentration available in the market . This makes it an ideal ingredient for supplement brands looking to develop effective cardiovascular health formulations backed by substantial clinical evidence.
Why Omega-7 Matters for Cardiovascular Health
Palmitoleic acid, the primary form of Omega-7, functions asa powerful ally against multiple cardiovascular risk factors. This unique fatty acid operates through five distinct mechanisms to combat metabolic syndrome effects: reducing insulin resistance, lowering blood glucose, suppressing fat production, normalizing lipid profiles, and fighting obesity.
In fact, Clinical research demonstrates Omega-7’s remarkableability to reduce atherosclerotic lesions by 45% and decrease circulatingtriglycerides by 30%. Additionally, studies show Omega-7supplementation can lead to significant reductions in LDL cholesterol whilesimultaneously increasing beneficial HDL cholesterol.
One of Omega-7’s most impressive attributes is its potentanti-inflammatory action. In a pilot trial with adults having high inflammation markers, just 210mg daily of Omega-7 resulted in a striking 73% decrease inC-reactive protein (CRP). This anti-inflammatory effect appears linked to Omega-7’s ability to deactivate the master inflammatory regulation complex called NF-kappaB.
Moreover, Omega-7 acts as a lipokine—a signaling molecule that positively affects organs beyond where it’s stored. This explains its multifaceted benefits for cardiovascular health.
For supplement manufacturers, these clinical findings present a compelling opportunity. Formulations containing high-quality Omega-7from Sea Buckthorn can address several cardiovascular health markers simultaneously, creating differentiated products backed by substantial research.
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
